CN113842373B - 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 - Google Patents
一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 Download PDFInfo
- Publication number
- CN113842373B CN113842373B CN202110999304.3A CN202110999304A CN113842373B CN 113842373 B CN113842373 B CN 113842373B CN 202110999304 A CN202110999304 A CN 202110999304A CN 113842373 B CN113842373 B CN 113842373B
- Authority
- CN
- China
- Prior art keywords
- egdma
- hema
- ima
- bagasse xylan
- theanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 title claims abstract description 49
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 46
- 229940109262 curcumin Drugs 0.000 title claims abstract description 43
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 23
- 239000004148 curcumin Substances 0.000 title claims abstract description 23
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 title claims abstract 14
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title claims abstract 14
- 229920001221 xylan Polymers 0.000 claims abstract description 62
- 150000004823 xylans Chemical class 0.000 claims abstract description 62
- 241000609240 Ambelania acida Species 0.000 claims abstract description 59
- 239000010905 bagasse Substances 0.000 claims abstract description 59
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 54
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims abstract description 35
- 229940026510 theanine Drugs 0.000 claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 22
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims abstract description 18
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003999 initiator Substances 0.000 claims abstract description 12
- 229920000578 graft copolymer Polymers 0.000 claims abstract description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 10
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- PBIDWHVVZCGMAR-UHFFFAOYSA-N 1-methyl-3-prop-2-enyl-2h-imidazole Chemical compound CN1CN(CC=C)C=C1 PBIDWHVVZCGMAR-UHFFFAOYSA-N 0.000 claims abstract description 8
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000178 monomer Substances 0.000 claims abstract description 8
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 25
- 238000005303 weighing Methods 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 21
- 239000012153 distilled water Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 9
- 239000012065 filter cake Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000000967 suction filtration Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 claims 3
- 238000005886 esterification reaction Methods 0.000 abstract description 7
- 239000002028 Biomass Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 239000003054 catalyst Substances 0.000 abstract description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 201000002313 intestinal cancer Diseases 0.000 abstract description 3
- 239000002608 ionic liquid Substances 0.000 abstract description 3
- 238000003032 molecular docking Methods 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000007348 radical reaction Methods 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 6
- 230000032050 esterification Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229920002488 Hemicellulose Polymers 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002479 acid--base titration Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- -1 alkyl imidazole Chemical compound 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F285/00—Macromolecular compounds obtained by polymerising monomers on to preformed graft polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/13—Phenols; Phenolates
- C08K5/132—Phenols containing keto groups, e.g. benzophenones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110999304.3A CN113842373B (zh) | 2021-08-28 | 2021-08-28 | 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110999304.3A CN113842373B (zh) | 2021-08-28 | 2021-08-28 | 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113842373A CN113842373A (zh) | 2021-12-28 |
CN113842373B true CN113842373B (zh) | 2023-05-05 |
Family
ID=78976482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110999304.3A Active CN113842373B (zh) | 2021-08-28 | 2021-08-28 | 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113842373B (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109438622A (zh) * | 2018-10-21 | 2019-03-08 | 桂林理工大学 | 离子液体中合成抗癌活性苯丙氨酸酯化蔗渣木聚糖-g-CHMA的方法 |
CN110128593A (zh) * | 2019-05-28 | 2019-08-16 | 桂林理工大学 | 离子液体中合成蔗渣木聚糖香草酸酯-g-HEMA/MAA的方法 |
CN110885404A (zh) * | 2019-10-22 | 2020-03-17 | 桂林理工大学 | 一种活性蔗渣木聚糖乙酰苯丙氨酸酯-g-VAc的合成方法 |
CN110724232A (zh) * | 2019-10-22 | 2020-01-24 | 桂林理工大学 | 一种活性蔗渣木聚糖柠檬酸酯-g-GMA的合成方法 |
CN112094376A (zh) * | 2020-09-06 | 2020-12-18 | 桂林理工大学 | 一种离子液体中合成蔗渣木聚糖原儿茶酸酯-g-HEMA/MAA的方法 |
-
2021
- 2021-08-28 CN CN202110999304.3A patent/CN113842373B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113842373A (zh) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107417857B (zh) | 抗癌活性衍生物蔗渣木聚糖丁香酸酯-g-AM/MMA的合成方法 | |
CN104531118B (zh) | 一种智能纳米驱油剂的制备方法 | |
CN107550921B (zh) | 一种纳米颗粒-高分子可注射复合水凝胶双载药体系及其制备方法 | |
CN103087257B (zh) | pH和温度双重敏感的离子微水凝胶的制备方法 | |
CN104823970B (zh) | 一种载药Pickering乳液的制备方法 | |
CN104592702A (zh) | 可自愈合的有机物/无机纳米粒子杂化材料及其制备方法 | |
CN100443508C (zh) | 具有快速磁场响应性的功能高分子复合微球的制备方法 | |
CN107652441B (zh) | 一种SiO2增强型聚合物微球制备方法 | |
CN103724555B (zh) | 一种热塑性弹性体的制备方法 | |
CN101910256A (zh) | 用于稳定类胡萝卜素的双层聚合物胶囊及其制备方法以及含有该聚合物胶囊的化妆品组合物 | |
CN102145173A (zh) | 人血清白蛋白复合的疏水改性普鲁兰多糖纳米粒子及制备方法 | |
CN102010488A (zh) | 一种温敏性可降解微水凝胶及其制备和应用 | |
CN103694379B (zh) | 一种具有光和pH响应特性的两嵌段共聚物及其制备方法 | |
CN111087513B (zh) | 一种双亲性表面活性剂的制备方法及两性离子纳米中空胶囊的可控制备方法 | |
CN104761673B (zh) | 一种卡波姆及其制备方法 | |
CN113842373B (zh) | 一种姜黄素包裹LTBX-g-EGDMA/HEMA/IMA纳米粒的制备方法 | |
CN112341641B (zh) | 一种双网络颗粒凝胶及其制备方法 | |
CN108641092B (zh) | 基于氢键的超分子聚合物复合胶束的制备方法 | |
CN105778112B (zh) | 一种两亲性pH值响应性三元刷聚合物和纳米多孔胶囊 | |
CN112679666A (zh) | 一种可快速高效分离刺激响应性星形及线形聚合物的方法 | |
CN101457007B (zh) | 一种多头型聚合物复合微球及其制备方法 | |
Saraf et al. | Extraction, structural properties, and applications of guar gum | |
CN108219062A (zh) | 一种光诱导电子转移-可逆加成断裂链转移聚合制备有机多孔材料的方法 | |
CN113736024A (zh) | 一种蔗渣木聚糖琥珀酸酯-g-HEMA/EGDMA-Cur的制备方法 | |
CN113698538A (zh) | 一种负载姜黄素的LTBX-g-HEMA/EGDMA纳米粒的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211228 Assignee: GUILIN XINYU GE INDUSTRY Co.,Ltd. Assignor: GUILIN University OF TECHNOLOGY Contract record no.: X2023980044185 Denomination of invention: A Preparation Method of Curcumin Encapsulated LTBX-g-EGDMA/HEMA/IMA Nanoparticles Granted publication date: 20230505 License type: Common License Record date: 20231025 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211228 Assignee: Guangxi Kaitian agricultural new technology Co.,Ltd. Assignor: GUILIN University OF TECHNOLOGY Contract record no.: X2023980045085 Denomination of invention: A Preparation Method of Curcumin Encapsulated LTBX-g-EGDMA/HEMA/IMA Nanoparticles Granted publication date: 20230505 License type: Common License Record date: 20231030 Application publication date: 20211228 Assignee: Guangxi conglomeration Energy Technology Co.,Ltd. Assignor: GUILIN University OF TECHNOLOGY Contract record no.: X2023980045081 Denomination of invention: A Preparation Method of Curcumin Encapsulated LTBX-g-EGDMA/HEMA/IMA Nanoparticles Granted publication date: 20230505 License type: Common License Record date: 20231030 |